Form 4: Pyxis Oncology Director Santhosh Palani Acquires Stock Options
SEC Form 4 Filing
Director Santhosh Palani acquired stock options in Pyxis Oncology, Inc. on March 31, 2025.
Summary
- On March 31, 2025, Santhosh Palani, a director of Pyxis Oncology, Inc., acquired stock options to purchase 36,979 shares of common stock.
- The exercise price of the stock options is $0.98 per share.
- The options vest 100% on the first anniversary of the grant date, contingent upon continued service.
- The expiration date for the options is March 31, 2035.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is neither overtly positive nor negative.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future prospects.
Industry Context
This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.
Stakeholder Impact
- The acquisition of stock options by a director could have a slightly positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: Director Santhosh Palani acquired stock options. |
| 03/31/2026 | Vesting date: The stock options vest 100% on this date, subject to continued service. |
| 03/31/2035 | Expiration date: The stock options expire on this date. |
Keywords
stock options, Form 4, director, PYXS, Pyxis Oncology, beneficial ownership
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.